<DOC>
	<DOCNO>NCT01313273</DOCNO>
	<brief_summary>The aim study compare exploratory fashion efficacy progression-free survival lanreotide addition non steroidal anti androgens LHRH-a non metastatic castrate resistant prostate cancer patient .</brief_summary>
	<brief_title>Study Lanreotide Non Metastatic Castration-resistant Prostate Cancer Patients</brief_title>
	<detailed_description>LHRH-a=Luteinizing Hormone-Releasing Hormone Analogues</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Nonsteroidal Anti-Androgens</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>Histologically proven diagnosis prostate cancer Evidence PSA progression despite castrate level testosterone ( &lt; 50 ng/dL ) follow orchiectomy therapy luteinizing hormone release hormone agonist ( LHRHa ) Patients nonmetastatic stable metastatic disease Chromogranin A elevation normal range ( confirmed second evaluation least 1 week later ) [ cut level &gt; 20 U/L enzyme link immunosorbent ( ELISA ) assay &gt; 100 ng/ml immunoradiometric ( IRMA ) assay ] Patients accord investigator opinion candidate treat immediately chemotherapy ( e.g . docetaxel ) First line treatment antiandrogen monotherapy Visceral metastasis Previous concomitant treatment somatostatin analogue</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>